Browsing Modes for Business Users

Mumps Virus

ISO 9001 Quality Assurance Manufacturing | Print
Native Mumps Virus thumbnail image 1 Native Mumps Virus thumbnail image 2
Native Mumps Virus gallery image 1
Published customer image:
Inactivated Mumps virus, Enders strain (PIP014) used as a target antigen for the evaluation of patient seropositivity by ELISA.
Image caption:
Simple dot plot representation of anti-measles IgG seropositivity ratios. During result computation, no discrimination was made between immune responses elicited by vaccination and those triggered by natural infection, including subsequent seroconversion. The analysis relied on quantitative data obtained through immunoassays (ELISAs), which were then translated into qualitative outcomes (positive or negative). Seropositivity = number of positive samples per age group/total number of samples per age group × 100. Dots are connected solely to facilitate visual tracking of consistent trends between countries, serving the purpose of facilitating easy interpretation based on direct observation. (a) Anti-mumps IgG seropositivity ratios;

From: Szinger, D.; Berki, T.; Drenjančević, I.; Samardzic, S.; Zelić, M.; Sikora, M.; Požgain, A.; Markovics, Á.; Farkas, N.; Németh, P.; et al.
Raising Epidemiological Awareness: Assessment of Measles/MMR Susceptibility in Highly Vaccinated Clusters within the Hungarian and Croatian Population—A Sero-Surveillance Analysis.
Vaccines 2024, 12, 486.
doi: 10.3390/vaccines12050486
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Native Mumps Virus gallery image 2
Published customer image:
Inactivated Mumps virus, Enders strain (PIP014) used as a target antigen for the evaluation of patient seropositivity by ELISA.
Image caption:
Assessing nonoverlapping confidence intervals for age group comparison. The Clopper–Pearson exact binomial confidence interval was used as a statistical method in order to calculate the confidence interval for a proportion regarding our binomial data (positive or negative seropositivity outcomes). The absence of overlap in confidence intervals (CI 95%) was interpreted as indicative of a statistically significant difference between the respective age groups. For detailed analysis, structured in a clear, table-based design, highlighting only the nonoverlapping confidence intervals between age groups.

From: Szinger, D.; Berki, T.; Drenjančević, I.; Samardzic, S.; Zelić, M.; Sikora, M.; Požgain, A.; Markovics, Á.; Farkas, N.; Németh, P.; et al.
Raising Epidemiological Awareness: Assessment of Measles/MMR Susceptibility in Highly Vaccinated Clusters within the Hungarian and Croatian Population—A Sero-Surveillance Analysis.
Vaccines 2024, 12, 486.
doi: 10.3390/vaccines12050486
This image is from an open access article distributed under terms of a Creative Commons Attribution License.

Native Mumps Virus

Product Type
Antigen
Specificity
Mumps Virus

Quick Links:

 Antibody Quality and Performance Guarantee
 Unrivaled Technical Support
Product Code Applications Pack Size List Price Your Price Qty
PIP014
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
E 1 ml loader
List Price Your Price
loader

Native mumps virus preparation Native mumps virus contains a high concentration of virus and viral components. The preparation also contains some cellular material suspended in tissue culture medium (1969B).

Mumps virus is a member of the Paramyxoviridae family and is the causative agent of mumps. Mumps is most typically characterised by painful swelling of the salivary glands and fever. In some adult men, the virus might also infect the testicles, rarely causing sterility. The virus is spread by airborne droplets from the nose or throat and can have an incubation period of up to three weeks. Infected individuals are contagious from approximately 6 days before until about 9 days after the onset of symptoms. The disease is self-limiting and treatment involves controlling specific symptoms. An effective vaccine exists and may be given separately or as part of the MMR vaccine.

Target Species
Viral
Product Form
Inactivated Mumps virus - liquid
Preparation
Mumps virus, Enders strain, cultured in BSC-1 cells. Optimally infected cells are harvested, disrupted by sonication in culture medium and subjected to low speed centrifugation. The supernatant from the infected culture is concentrated by crossflow ultrafiltration. The antigen preparation is inactivated using gamma radiation, which primarily damages viral genetic material.
Buffer Solution
Culture medium 1969B
Preservative Stabilisers
None present
Activity
Antigenic activity is 51.1% of internal reference batch
Approx. Protein Concentrations
Current, batch-specific concentration 1.0 mg/ml
Regulatory
For research purposes only
Guarantee
12 months from date of despatch

Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Instructions For Use
PIP014
PIP014 should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats or may be further purified to meet the requirements of a particular assay format.

References for Mumps Virus

  1. Bhoj, V.G. et al. (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.
    Blood. 128 (3): 360-70.
  2. Riggenbach, M.M. et al. (2021) Mumps virus-specific immune response outcomes and sex-based differences in a cohort of healthy adolescents.
    Clin Immunol. 234: 108912.
  3. Böröcz, K. et al. (2022) Dynamic Features of Herd Immunity: Similarities in Age-Specific Anti-Measles Seroprevalence Data between Two Countries of Different Epidemiological History.
    J Clin Med. 11(4):1145.
  4. Wang, L. et al. (2023) Associations of adaptive immune cell subsets with measles, mumps, and Rubella−Specific immune response outcomes
    Heliyon. 9 (12): e22998.
  5. Ovsyannikova, I.G. et al. (2023) Genome-wide determinants of cellular immune responses to mumps vaccine.
    Vaccine. 41 (44): 6579-88.
  6. Szinger, D. et al. (2023) Following Natural Autoantibodies: Further Immunoserological Evidence Regarding Their Silent Plasticity and Engagement in Immune Activation.
    Int J Mol Sci. 24 (19)Oct 06 [Epub ahead of print].
  7. Szinger, D. et al. (2024) Raising Epidemiological Awareness: Assessment of Measles/MMR Susceptibility in Highly Vaccinated Clusters within the Hungarian and Croatian Population—A Sero-Surveillance Analysis
    Vaccines. 12 (5): 486.

UniProt
P21277
GO Terms
GO:0003723 RNA binding
GO:0030529 ribonucleoprotein complex
GO:0005198 structural molecule activity
GO:0019013 viral nucleocapsid
GO:0030430 host cell cytoplasm

PIP014

149234 151308 151309 155669 155926 158888

If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.

Request a different product with this specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

View all Anti-Viral Products
Please note